Adoptive T cell therapy: engineering and biomanufacturing chimeric antigen receptor-T cell

Development of Chimeric Antigen Receptor (CAR)-T cells is revolutionizing the field of cell therapy. Since its inception, research has been focused on improving the effectiveness, accessibility, and safety of CAR-T cell therapy. To achieve this, the biomanufacturing process must be scaled and optimized to match increasing demand. The current processes of engineering, activating, expanding, and purifying CAR-T cells have improved in recent years, but significant challenges in process scaleup and consistency remain. Additionally, engineering efforts now aim to enhance CAR-T cell therapy with ‘armored’ CAR-T cells to improve solid tumor penetration and immune system response to cancer. This review highlights the current processes and challenges in biomanufacturing and engineering CAR-T cells to improve its success in cancer treatment.